+34 679 490 537info@nanbiosis.com

ICTS

ICTS

NANBIOSIS- OmicsTech: EXPLORING COLLABORATIONS BETWEEN ICTS FACILITIES

Last week, representatives of NANBIOSIS and OmicsTech met at the IQAC-CSIC facilities in Barcelona to exchange common research lines, points of view of their complementarity and collaboration possibilities of the facilities, both recognized as Unique Scientific Technical Infrastructure (ICTS) by the Spanish Government.

The Infrastructure for Omics Technologies OmicsTech ICTS is a distributed infrastructure that offers researchers the possibility of using globally competitive singular facilities exclusively dedicated to work with omics technologies, with a spectrum of biomolecular analysis tools for holistic capture of biological processes, to support research, technological development, and innovation activities. Advances in genomics, proteomics and metabolomics technologies have opened new avenues towards understanding molecular disease mechanisms and the behavior of cells, tissues, organs and, eventually, whole organisms. OmicsTech is formed by the Center of Omic Sciences (COS-URV-EURECAT), Centro Nacional de Análisis Genómico (CNAG-CRG) and the Proteomics Platform-CRG (PP-CRG-UPF).

The Infrastructure for the Production and Characterization of Nanomaterials, Biomaterials and Systems in Biomedicine NANBIOSIS ICTS is a distributed infrastructure for biomedical research with outsourcing equipment and expertise of excellence to design and produce biomaterials, nanomaterials and their nanoconjugates as well as their characterization from a physic-chemical, functional, toxicological and biological (preclinical validation) point of view, focused on biomedical applications such as: IVDs, medical devices, biosensors, regenerative medicine, drug delivery systems, therapeutic agents or MRI contrast agents. NANBIOSIS provides more than 700 accesses per year and services to 100 companies.

Due to this complementarity, both ICTS facilities have explored collaborations possibilities and a list of initiatives were discussed. This new collaboration will start with a session of OmicsTech in the Annual Conference of CIBER-BBN that will take place next October 21-22 in Tarragona. Meanwhile, both ICTS will work together stablishing synergies between different services that both institutions provide increasing the scope of the biomedical solutions given to the health sector. Collaboration between groups of the CIBER-BBN and groups related to OmicsTech will additionally facilitate the synergies between the two ICTS facilities.

For further information:

www.nanbiosis.es; www.omicstech.org

Read More

Job Vacancy for position of Project Manager at CIBER

Scientist aiming at developing a career in project management is required for a European Project in the field of biomedical research; working with NANBIOSIS ICTS (Scientific infraestructure of CIBER-BBN). The position requires good command of English and strong skills in coordinating researchers.

Applications must be filed at CIBER’s web portal untill May 22.

Read More

Safe-N-Medtech kicks off in Bilbao

The Safe-N-MedTech European Project kcks off in Bibao to create an open innovation platform that accelerates the development of medical devices based on nanotechnologies.

During 2 and 3 of May took place in Bilbao, at the University of the Basque Country, the kick off meeting of the European project Safe-N-Medtech organized by Osteba, the HTA Unit of the Ministry of Health of the Basque Country (Spain) in collaboration with BIOPRAXIS-BIOKERALTY.

Safe-N-Medtech, counts with 28 partnerts coordinated by TECNAN (Navarran company with great experience in Nano products), together with BIOPRAXIS-BIOKERALTY, the research branch of the global health companies Keralty and Praxis. The new project is part of the Open Innovation Test Bed initiative (OITB) launched by the European Commission with the aim of accelerating the development of medical devices based on nanotechnologies in Europe and abroad. The project has a European funding of 15 million euros.

CIBER-BBN participates as a partner in the Safe-N-Medtech throught its Scientific Infraestructure, the ICTS NANBIOSISSeveral units of NANBIOSIS from CIBER-BBN and JUMISC wiil carry out some of the F/Q, in vivo and in vitro characterizations applied to pilot test cases, NANBIOSIS is the leader of WP3 Preclinical Research in nano-enabled MTs.

Society and clinical practice raise a growing demand for new biomaterials, ICTs, medical devices and in vitro diagnostics (Medical Technologies-MTs) based on micro and nanotechnologies. In addition to the challenge of time, new technologies are subject to other pressing factors, such as qualification, regulation, cost, biocompatibility and the need to be applicable throughout the world. Medical devices based on nanotechnologies can be applied in almost all medical areas, with an important presence in areas such as cancer, regenerative medicine, advanced therapies, neurology, cardiology, orthopedics and dentistry.

The initiative aims to build an open innovation platform to offer companies and reference laboratories the capabilities, knowledge, networks and services necessary for the development, testing, evaluation, improvement and exploitation of the market of medical devices and diagnostic based in nanotechnology. This platform will offer a multidisciplinary and market-oriented innovation approach for SMEs, health care providers and industries, accelerating the transfer to the market of these new medical devices. During the first years of project work, the partners will develop their services and test them in different case studies, so that, Safe-N-Medtech OITB can become a sustainable and competitive services platform for companies to accelerate their developments according to the necessary regulatory requirements and ensure the safety and effectiveness of their medical devices based on nanotechnologies.

Read More

Why peripheral blood lymphocyte alterations can be good biomarkers to predict myocardial infarction severity

Researchers of CCMIJU led by Verónica Crisóstomo, Scientific Director of NANBIOSIS U24 Medical imaging, and Javier García Casado Scientific Director of NANBIOSIS U14 Cell Therapy unit have carried out a study study aimed to identify which are the very early immune-related biomarkers that may be used as predictors of myocardial infarction severity.

Experimental studies have been conducted by NANBIOSIS Units 14, 21, 22 and 24 of the CCMIJU, clinical test lab, animal housing, experimental operating room and medical imaging tecniciansare are recognized in the acknowledgement and funding sections of the article.

Article of reference:

Esther López, Francisco Miguel Sánchez-Margallo, Verónica Álvarez, Rebeca Blázquez, Federica Marinaro, Ana Abad, Helena Martín, Claudia Báez,Virginia Blanco,Verónica Crisóstomo and Javier García Casado “Identification of very early inflammatory markers in a porcine myocardial infarction model” BMC Veterinary Research 2019-15:91

Read More

The European Union highlights the relevance of the JUMISC’s Cutting-Edge Infraestructures and Technology, recognized as ICTS.

Jesús Usón Minimally Invasive Surgery Center (JUMISC), from Cáceres, partnert of NANBIOSIS, has recently made headlines on the website of the European Commission as an innovative center for Biomedical and Health Research.

In the interview to his Director, Francisco Miguel Sanchez Margallo, he explained how European Funds allowed Infraestructures and Vanguard Technology for biomedical research at the CCMIJU, which have already been recognized, as part of NANBIOSIS, with CIBER-BBN and BIONAND, as “Singular Scientific and Technical Infrastructure” (ICTS).

Complete news at European Commision’s Website: https://ec.europa.eu/spain/news/investeu_caceres_es

https://ec.europa.eu/spain/news/investeu_caceres_es
Read More

Bionand, recently incorporated to NANBIOSIS ICTS, among the three national biotechnology reference centers.

The Diario Sur of  Andalucía, publishes today  an article dedicated to BIONAND and its recent accreditation as ICTS by the Ministry of Science, Innovation and Universities, that resolved on November 6 the incorporation of the Nanoimaging Unit of BIONAND to the ICTS NANBIOSIS.

In the article, the Director of BIONAND, Jose Becerra Ratia, Professor of Cell Biology of the University of Malaga, explains the opportunities and commitments that imply for the Andalusian Center for Nanomedicine and Biotechnology (BIONAND) its incorporation to NANBIOSIS.

Read More

EXPLORING COLLABORATIONS BETWEEN ICTS FACILITIES

Members of the NANBIOSIS Coordination Committee have visited the ALBA Synchrotron and its representatives to exchange common research lines, points of view on their complementarity and discuss the collaboration possibilities of the facilities,  both recognized as Unique Scientific Technical Infrastructure  (ICTS) by the Spanish Government.

The ALBA Synchrotron consists of a complex of electron accelerators in which the electrons are forced to rotate at a speed of 1 million turns per second. When they are bent, synchrotron light is emitted, allowing to visualize the atomic structure and molecular analysis of materials and study their properties obtaining information that cannot be achieved in any other way.

ALBA offers synchrotron light to external users, both from the academia and from the industry, to perform outstanding studies of a very wide range of research sectors. It provides services to 1800 researchers per year performing more than 500 experiments.

Currently, ALBA has eight operational state-of-the art beamlines, four are under construction  and it has capacity for more than twenty beamlines, in total. Five of these beam lines are focused on biomedical applications. It is in these beamlines where the services of ALBA Synchrotron are complementary to those of NANBIOSIS, especially in the field of Structural / biochemical Characterization.

NANBIOSIS is a distributed infrastructure for biomedical research with outsourcing equipment and expertise of excellence to design and produce biomaterials, nanomaterials and their nanoconjugates as well as their characterization from a physic-chemical, functional, toxicological and biological (preclinical validation) point of view, focused on biomedical applications such as: IVDs, medical devices, biosensors, regenerative medicine, drug delivery systems, therapeutic agents or MRI contrast agents. NANBIOSIS provides more than 700 accesses per year and services to 100 companies.

Due to this complementarity, both ICTS facilities have explored collaborations possibilities and a list of initiatives were discussed. The starting point will be to put in common all the different services that both institutions provide in order to meet the most complex needs of its users and increase the scope of the biomedical solutions given to the health sector.

This new collaboration started with a presentation of ALBA and its complementarity with NANBIOSIS in the annual Conference of CIBER-BBN that took place in November 11-13 in Valladolid.

More information:

NANBIOSIS

ALBA Synchrotron

https://www.cells.es/en

Contact:

Contact Nanbiosis:  info@nanbiosis.com

Contact ALBA Synchrotron: industrialoffice@cells.es

 

Read More

NANBIOSIS renews its accreditation as Unique Scientific Technological Infrastructure (ICTS)

NANBIOSIS is one of the 29 ICTS (Unique Scientific Technological Infrastructures) recognized by the Scientific, Technological and Innovation Policy Council (CPCTI) of the Ministry of Science, Innovation and Universities. On November 6, the Council approved the updating of the ICTS Map in which the accreditation of Nanbiosis is renewed as one of them.

The new Map is integrated by 29 ICTS, which bring together a total of 62 infrastructures, all of them operative. In the new update the number of ICTS is maintained, but the number of infrastructures is increased by the incorporation of new nodes to existing distributed ICTS.

NANBIOSIS offers complete services for the production and characterization of nanomaterials, biomaterials and systems in biomedicine. This ICTS is integrated by the CIBER-BBN and the Minimally Invasive Surgery Center Jesús Usón (CCMIJU) and the recent incorporation of Bionand in Málaga. It consists of 28 units distributed throughout the Spanish geography and coordinated under a single contact point. These units offer a complementary service tailored and turnkey projects that includes the design and production of biomaterials and nanomaterials and the characterization of these bio and nanomaterials, tissues, devices and medical systems from a point of view, physical-chemical, functional , toxicological and biological (including preclinical validation), focused on biomedical applications.

All this potential allows from developing a therapeutic agent until it reaches its preclinical validation and wrapped by the best Spanish research groups in bioengineering, biomaterials and nanomedicine.

ICTS map

The map of Singular Scientific and Technical Infrastructures is a planning and development tool for these infrastructures in coordination with the Autonomous Communities. The new ICTS Map approved by the Council is the result of a rigorous independent evaluation process and consolidates the single location and distributed infrastructures.

The ICTS are available to the scientific, technological and industrial, national and international community. These avant-garde scientific-technical infrastructures, indispensable for the development of competitive and quality scientific and technological research, are unique in their kind, with a very high investment and / or maintenance cost and operation and whose strategic nature justifies their competitive access for the entire R & D & I system.

In addition to NANBIOSIS, Integrated Infrastructure of Production and Characterization of Nanomaterials, Biomaterials and Systems in Biomedicine, the ICTS in Health Sciences and Biotechnology are:

  • Integrated Infrastructure of Omic Technologies,
  • Network of Laboratories of High Biological Safety,
  • Distributed Network of Biomedical Image and
  • Network of Nuclear Magnetic Resonance Laboratories of Biomolecules.

 

The map is completed by another 24 ICTS in Astronomy and Astrophysics, Sciences of the Sea, Life and Earth; Information and Communications Technologies; Energy; Engineering; Materials; Socioeconomic Sciences and Humanities

Further information

Read More

NANBIOSIS develops on demand projects and cutting edge biomedical solutions.

In this video, Jesús Izco Ex. Director of NANBIOSIS, presents NANBIOSIS as one of the 29 ICTS that currently make up the national ICTS map. It consist consists of 27 units grouped into five platforms  which ofer their services under a single contact point and develops on demand projects and cutting edge biomedical solutions in different biomedical applications such as biosensors, live image, contrast agents, therapeutic agents, regenerative medicine, drug delivery, among others.

 

 

Read More

The PRO-NANBIOSIS II Network of Excellence begins its execution

The PRONANBIOSIS II Network of Excellence ICTS 2017 SAF2017-90810-REDI, granted by the Spanish Minitry of Science to NANBIOSIS, begins its activity planned for two years.

Networks of Excellence favor the development of networks of research groups aimed, in this case, to promote the general coordination of ICTS or Distributed ICTS, as is the case of NANBIOSIS.

This Network will give continuity to the previous PRONANBIOSIS Network, which ended on July 31st. The main purposes of the Network are:
– to consolidate its unified management model,
– to boost its internationalization and strategic positioning
– to promote a complete cascade service for nanomaterials characterization

Read More